PredicineCARE™ Liquid Biopsy Assay Featured in NEJM as Pivotal Tool in Roche's Phase III Itovebi Breast Cancer Trial
Roche(RHHBY) GlobeNewswire News Room·2024-11-05 01:28
PredicineCARE™ was utilized to identify and enroll patients with PIK3CA-mutated metastatic breast cancer in China, a key component contributing to the FDA’s approval of Inavolisib in the U.S. on October 10, 2024. HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, is pleased to announce the publication of a landmark study in The New England Journal of Medicine (NEJM). This study highlights the clinical utility of the PredicineCARE™ liquid biopsy assay ...